Purpose of this Study
Everyone in the study will get a medicine called Quisinostat.
The study will last about 3 years and has three parts:
- Screening Period – doctors check if you can join
- Treatment Period – you take the medicine
- Follow-Up Period – doctors check how you\'re doing after treatment
Who Can Participate?
Eligibility
Who can join this part of the study?
- Adults with a kind of eye cancer called UM, and the tumor must be a certain size
- The cancer must not have spread to other parts of the body
- They must have finished their main treatment (like surgery or radiation) within about 6 months
- They must be expected to live at least 3 more months
- Women who could have babies and men must agree to use birth control during the study and for 6 months after
Women must take a pregnancy test before joining to make sure they’re not pregnant
Age Range
18-110
Sex/Genders
Male (cisgender)
Female (cisgender)
Non-binary or gender fluid
Transgender male
Transgender female
Looking for Healthy Participants
No
What is Involved?
Description
The purpose of this study is to see if giving you quisinostat will prevent your uveal melanoma tumor from spreading
Locations
Duke University Hospital
Duke Raleigh Hospital
Visit Timing
Weekdays
Compensation
No
Spanish Materials Available
No
Study Details
Full Title
Phase 2 Trial of Adjuvant Quisinostat in High-Risk Uveal Melanoma
Principal Investigator
April
Salama
Protocol Number
PRO00118866
NCT ID
NCT06932757
Phase
II
Enrollment Status
Pending Open to Enrollment